Mayo Clinic

Running trials

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Source

• Recruiting

  A U.S. Pilot Human Investigation of RadiofrEquency Vapor Ablation System to Evaluate Safety, TOleRability, and Effectiveness for Proximal Intestinal Mucosal Ablation in Patients With Type 2 Diabetes Mellitus (RESTORE-1 Study)

  NCT07355270· Source

• Recruiting

  Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables

  NCT07012148· Early phase 1· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Source

• Recruiting

  A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

  NCT07216027· Phase 2· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Source

• Recruiting

  Sacral Neuromodulation for Male Overactive Bladder (MOAB)

  NCT06511141· Source

• Recruiting

  Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis

  NCT06201416· Phase 1· Source

• Recruiting

  Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

  NCT06385236· Phase 4· Source

• Active, not recruiting

  A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

  NCT06111235· Phase 3· Source

• Recruiting

  A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

  NCT06131840· Phase 1· Source

• Active, not recruiting

  A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

  NCT06052267· Phase 3· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

  NCT05714202· Phase 3· Source

• Enrolling by invitation

  An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

  NCT05667493· Phase 3· Source

• Active, not recruiting

  A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

  NCT05585320· Phase 1/2· Source

• Recruiting

  A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

  NCT05253651· Phase 3· Source

• Active, not recruiting

  A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

  NCT05217446· Phase 2· Source

• Active, not recruiting

  A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

  NCT05238883· Phase 1· Source

• Active, not recruiting

  A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

  NCT05132582· Phase 3· Source

• Active, not recruiting

  A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

  NCT05071300· Phase 3· Source

• Recruiting

  LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

  NCT04752722· Phase 1/2· Source

• Active, not recruiting

  Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

  NCT04526691· Phase 1· Source

• Active, not recruiting

  Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

  NCT04430738· Phase 2· Source

• Active, not recruiting

  Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)

  NCT03268603· Phase 2· Source

• Active, not recruiting

  A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

  NCT02773030· Phase 1/2· Source

• Recruiting

  Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

  NCT01492972· Phase 3· Source

• Recruiting

  Registry Study for Radiation Therapy Outcomes

  NCT01255748· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer3 recruiting
• Crohn's disease2 recruiting
• Prostate cancer2 recruiting
• Amyloidosis1 recruiting
• Asthma1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Epilepsy1 recruiting
• Gastric and esophageal cancer1 recruiting
• Lung cancer1 recruiting
• Neuroendocrine tumours1 recruiting
• Pancreatic cancer1 recruiting
• Rheumatoid arthritis1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring (ABPM)

  NCT07240831· Source

• Completed

  REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis

  NCT06788535· Phase 3· Source

• Completed

  Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis

  NCT05908240· Source

• Terminated

  Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics

  NCT05819827· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Source

• Completed

  MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer

  NCT05189171· Source

• Completed

  TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps

  NCT04998305· Phase 1/2· Source

• Terminated

  A Study of HFB301001 in Adult Patients With Advanced Solid Tumors

  NCT05229601· Phase 1· Source

• Terminated

  A Study to Investigate LYL797 in Adults With Solid Tumors

  NCT05274451· Phase 1· Source

• Completed

  A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

  NCT05014412· Phase 2· Source

• Terminated

  PF-07284892 in Participants With Advanced Solid Tumors

  NCT04800822· Phase 1· Source

• Completed

  Trial of Parkinson's And Zoledronic Acid

  NCT03924414· Phase 4· Source